Each SGLT2 inhibitor—empagliflozin, canagliflozin, dapagliflozin, and ipragliflozin—targets specific pathways and mechanisms, providing unique benefits in the management of T2DM and MASLD. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.